Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

ASCO 2026

29 May - 2 Jun 2026

Published: 1 Jun 2026

Views: 127

Rating:

Save

Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA

Dr Shailender Bhatia talks to ecancer at ASCO 2026 about results from the phase III ADAM trial evaluating adjuvant avelumab in patients with stage III Merkel cell carcinoma and lymph node metastases following definitive treatment.

The study showed that adjuvant avelumab reduced the risk of disease relapse compared with placebo, with sustained improvements in relapse-free survival and distant metastasis-free survival.

Dr Bhatia notes that these findings may help inform future discussions around the use of adjuvant immunotherapy in Merkel cell carcinoma.

Related Videos

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk...

Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia...

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma ( Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia, Sydney, Australia )

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic...

Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma ( Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

ASCO 2026: Breast cancer overview

Dr Hope Rugo - City of Hope, Duarte, USA

ASCO 2026: Breast cancer overview ( Dr Hope Rugo - City of Hope, Duarte, USA )

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell...

Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma ( Dr Pavlina Spiliopoulou - Beatson West of Scotland Cancer Centre, Glasgow, UK )

Machine learning models improve prediction of immunotherapy outcomes across...

Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types ( Dr Alyssa Pybus - Moffitt Cancer Center, Tampa, USA )

Denikitug shows immune activation and early anti-tumour activity in advanced...

Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA

Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour ( Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA )

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1...

Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA

Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers ( Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA )

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer ( Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain )

More from ecancer